Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention

Aim: resistin is an adipocytokine that may link inflammation and atherosclerosis.we studied the associations of resistin levels with cardiovascular events and restenosis. methods: we measured pre-procedural serum resistin levels in 140 patients with coronary artery disease undergoing elective percutaneous coronary intervention (pci),of whom 97 had a stent. restenosis was defined as >50% stenosis at follow-up angiography. patients were followed for 3 years for major adverse cardiovascular events (mace). results: at 8±6 months after pci,re-angiography was performed in 94 (67%) patients,of whom 42 had restenosis. between 42 patients with restenosis and 52 without restenosis,resistin (4.5±2.6 vs. 4.5 ±2.5 ng/ml) and c-reactive protein (crp) (median 0.70 vs. 0.70 mg/l) levels did not differ. during 3-year follow-up,mace occurred in 24 patients (1 death,21 unstable angina,2 stroke). compared with 116 patients without mace,24 with mace had higher resistin (5.4±2.4 vs. 4.3±2.5 ng/ml) and crp (1.30 vs. 0.60 mg/l) levels (p<0.05). patients with mace more often had resistin >4.0 ng/ml than without mace (75% vs. 35%,p<0.001). resistin correlated with crp levels (r = 0.31). to clarify the association between mace and resistin,patients were divided into 2 groups by resistin levels. kaplan-meier analysis showed a lower event-free survival rate in patients with resistin >4.0 ng/ml than without it (p<0.001). on multivariate analysis,resistin,but not crp,was an independent predictor of mace. the hazard ratio for mace was 3.6 (95%ci = 1.4-9.2) for resistin >4.0 ng/ml. conclusion: serum resistin levels were found to be associated with further cardiovascular events in patients undergoing pci.